Abstract #1176119: Development of New Onset, Protracted Hyperglycemia Triggered by COVID-19 Vaccination with Ultimate Resolution in an Individual without Prior Dysglycemia

https://doi.org/10.1016/j.eprac.2022.03.085Get rights and content

Introduction

Frequently, endocrinologists are asked for advice on COVID-19 vaccination. For patients with diabetes, promoting vaccination against COVID-19 is critical; research has shown a significantly increased risk of severe infection in these patients.

Notably, there appears to be a physiological connection between COVID-19 infection and hyperglycemia. There have been multiple cases of patients developing hyperglycemia after contracting COVID-19. In contrast, there are few reported cases of new onset hyperglycemia developing after the COVID-19 vaccination.

Section snippets

Case Description

We present the case of a 63-year-old woman with no significant past medical history. She maintained a healthy lifestyle and stable weight for several decades (BMI 24.3).

She received her first dose of the Pfizer COVID-19 vaccination in December 2020. Frequent workplace testing (weekly, between 12/4/20 and 2/12/21) documented no evidence of COVID-19 infection, and no symptoms of COVID-19 had occurred at any time before or after immunization.

Four days post-vaccination, she developed significant

Discussion

There have been several reports of new-onset diabetes following COVID-19 vaccination. However, to date, we identified no published case reporting complete resolution of diabetes. We hypothesize that immune changes resulting from her COVID vaccine were associated with increases in inflammatory markers causing temporary beta cell toxicity. It is unclear what the impact of a booster will be on her glycemic control, therefore we recommend she remain vigilant for symptoms of hyperglycemia after

References (0)

Cited by (0)

View full text